FDA Approves Revolution Medicines' Pancreatic Cancer Drug Daraxonrasib; BeiGene Holds Asia Rights

On August 26, U. S. biopharmaceutical company Revolution Medicines announced that the U. Food and Drug Administration (FDA) approved Daraxonrasib (brand name: RASONQUE) for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy, or who are unsuitable for combination multi-drug systemic therapy. The drug is now available by prescription in the United States, administered orally once daily. The approval came approximately 6.5 months ahead of the original target date. BeiGene has obtained exclusive development and commercialization rights for the drug in select Asian markets, including China.

Pancreatic cancer is often called the "king of cancers," with pancreatic ductal adenocarcinoma accounting for 95% of cases. It is characterized by difficulty in early diagnosis, low surgical resection rates, and extremely poor prognosis, with mortality rates closely mirroring incidence rates. Pancreatic ductal adenocarcinoma harbors RAS gene mutations, predominantly KRAS, which has long been regarded as one of the most challenging drug targets. For years, the development of targeted therapies against KRAS has struggled to achieve breakthroughs.